More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment

Abstract

The NOTCH1 gene encodes a transmembrane receptor protein with activating mutations observed in many T¿cell acute lymphoblastic leukemias (T¿ALLs) and lymphomas, as well as in other tumor types, which has led to interest in inhibiting NOTCH1 signaling as a therapeutic target in cancer. Several classes of Notch inhibitors have been developed, including monoclonal antibodies against NOTCH receptors or ligands, decoys, blocking peptides, and ¿¿secretase inhibitors (GSIs). GSIs block a critical proteolytic step in NOTCH activation and are the most widely studied. Current treatments with GSIs have not successfully passed clinical trials because of side effects that limit the maximum tolerable dose. Multiple ¿¿secretase¿cleavage substrates may be involved in carcinogenesis, indicating that there may be other targets for GSIs. Resistance mechanisms may include PTEN inactivation, mutations involving FBXW7, or constitutive MYC expression conferring independence from NOTCH1 inactivation. Recent studies have suggested that selective targeting ¿¿secretase may offer an improved efficacy and toxicity profile over the effects caused by broad¿spectrum GSIs. Understanding the mechanism of GSI¿induced cell death and the ability to accurately identify patients based on the activity of the pathway will improve the response to GSI and support further investigation of such compounds for the rational design of anti¿NOTCH1 therapies for the treatment of T¿ALL.